The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Rescue Use and Night-Time Awakenings

Autor:	C.E. Jones, Robert A. Wise, G.J. Criner, David A. Lomas, Dave Singh, David A. Lipson, M.C. Kaisermann, Mark T. Dransfield, MeiLan K. Han, Sally Kilbride, Peter Lange, Fernando J. Martinez, Steven Pascoe, Dmg Halpin
Rok vydání:	2019
Předmět:	medicine.medical_specialty COPD UMECLIDINIUM/VILANTEROL business.industry Internal medicine Inhaler medicine In patient business medicine.disease Fluticasone furoate/vilanterol Fluticasone propionate medicine.drug
Zdroj:	B45. COPD: TREATMENT.
DOI:	10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3347
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::78f9fdc517bb7f4e9bc8e21bc5109386 https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3347 Zobrazit plný text záznamu